Skip to main content
SpringerLink
Log in

Psychopharmacology in Children with PDD: Review of Current Evidence

  • Chapter
  • First Online:
Evidence-Based Practices and Treatments for Children with Autism

Abstract

Over the past 20 years, there has been an increase in the identification of children with autism and phenotypically related conditions, Asperger disorder, and pervasive developmental disorder not otherwise specified (PDD-NOS) (Fombonne 2005). This increased recognition has brought in its wake greater demand for interventions – educational, psychosocial and psychopharmacological. A look at the literature over the past 20 years shows a rather impressive list of medications that have been examined in children with pervasive developmental disorders (PDDs) – albeit with varying degrees of rigor. These include antipsychotics, such as haloperidol and risperidone, alpha-2 agonists, such as clonidine and guanfacine, methylphenidate, antidepressants and the gastrointestinal hormone, secretin. In addition, medication such as fenfluramine, amantadine, and naltrexone has been examined in at least one study. To date, the best-studied medication in children with PDD is secretin, which has been examined in approximately 13 placebo-controlled trials (Levy and Hyman 2005). It has yet to show superiority to placebo. Although several medications have been evaluated for treatment of children with PDD, only a handful of trials have included more than 40 subjects. Over the past decade, however, evidence has emerged on the use of risperidone, the selective serotonin reuptake inhibitors (SSRIs), fluoxetine and citalopram, and methylphenidate in children with PDDs. Coincidently, these three classes of medication are also among the most commonly used in this population (Aman et al. 2003; Oswald and Sonenklar 2007; Mandell et al. 2008). This chapter reviews results from recently published reports mostly from federally-funded, multi-site randomized clinical trials. The review is organized according to target symptoms for medication intervention in children with PDDs, such as hyperactivity and impulsiveness, repetitive behavior, and the triad seriously maladaptive behavior: tantrums, aggression, and self-injury.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ADHD:

Attention deficit hyperactivity disorder

CARS:

Childhood Autism Rating Scale

CGI-I:

Clinical global impression-Improvement

CYBOCS:

Children’s Yale-Brown Obsessive–Compulsive Scale

DSM-IV-TR:

Diagnostic and Statistical Manual of Mental Disorders, 4th edition

FDA:

Food and Drug Administration

HSQ:

Home Situations Questionnaire

OCD:

Obsessive–compulsive disorder

PDD:

Pervasive developmental disorder

PDD-NOS:

Pervasive developmental disorder, not otherwise specified

RUPP:

Research Units on Pediatric Psychopharmacology

SSRI:

Selective serotonin reuptake inhibitor

STAART:

Studies to Advance Autism Research and Treatment

References

  • Aman, M. G., Lam, K., & Collier-Crespin, A. (2003). Prevalence and patterns of use of psychoactive medicines among individuals with autism in the autism society of Ohio. Journal of Autism and Developmental Disorders, 33(5), 527–534.

    Article  PubMed  Google Scholar 

  • Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavioral problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143–1154.

    Article  PubMed  Google Scholar 

  • APA. (2000). Diagnostic and Statistical Manual of Mental Disorders (4th ed. – text revision). Washington, DC: American Psychiatric Association.

    Google Scholar 

  • Biederman, J., Melmed, R. D., Patel, A., et al. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121(1), e73–e84.

    Article  PubMed  Google Scholar 

  • Brown, E., Aman, M., & Havercamp, S. (2002). Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. Research in Developmental Disabilities, 23, 45–60.

    Article  PubMed  Google Scholar 

  • Bussing, R., Fernandez, M., Harwood, M., Hou, W., Garvan, C., & Eyberg, S. (2008). Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: Psychometric properties and normative ratings from a school district sample. Assessment, 15(3), 317–328.

    Article  PubMed  Google Scholar 

  • Campbell, M., Anderson, L., & Cohen, I. (1982). Haloperidol in autistic children: Effects on learning, behavior, and abnormal involuntary movements. Psychopharmacology Bulletin, 18(1), 110–111.

    Google Scholar 

  • Fombonne, E. (2005). Epidemiology of autistic disorder and other pervasive developmental disorders. Journal of Clinical Psychiatry, 66(Suppl. 10), 3–8.

    PubMed  Google Scholar 

  • Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health. on p. 243

    Google Scholar 

  • Handen, B. L., Sahl, R., & Hardan, A. Y. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29(4), 303–308.

    Article  PubMed  Google Scholar 

  • Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., & Wasserman, S. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30(3), 582–589.

    Article  PubMed  Google Scholar 

  • Horrigan, J. P., & Barnhill, L. J. (1995). Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. Journal of Child and Adolescent Psychopharmacology, 5(3), 215–223.

    Article  Google Scholar 

  • Jaselskis, C., Cook, E., Fletcher, K., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322–327.

    Article  PubMed  Google Scholar 

  • Johnson, C. R., Handen, B. L., Butter, E., Wagner, A., Mulick, J., & Sukhodolsky, D. G. (2007). Development of a parent management training program for children with pervasive developmental disorders. Behavioral Interventions, 22, 1–21.

    Article  Google Scholar 

  • King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590.

    Article  PubMed  Google Scholar 

  • Kolevzon, A., Mathewson, K., & Hollander, E. (2006). Selective serotonin reuptake inhibitors in autism: A review of efficacy and tolerability. Journal of Clinical Psychiatry, 67, 407–414.

    Article  PubMed  Google Scholar 

  • Levy, S., & Hyman, S. (2005). Novel treatments for autistic spectrum disorders. Mental Retardation and Developmental Disabilities Research Reviews, 11, 131–142.

    Article  PubMed  Google Scholar 

  • Luby, J., Mrakotsky, C., Salets, M., Belden, A., Heffelfinger, A., & Williams, M. (2006). Risperidone in preschool children with autistic disorders: An investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology, 16(5), 575–587.

    Article  PubMed  Google Scholar 

  • Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121(3), e441–448.

    Article  PubMed  Google Scholar 

  • McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., et al. (2005). Risperidone for the core symptom domains of autism: Results from the RUPP Autism Network study. American Journal of Psychiatry, 162, 1142–1148.

    Article  PubMed  Google Scholar 

  • MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073–1086.

    Article  Google Scholar 

  • Neuropharm Group. (2009). Phase III SOFIA study of NPL-2008 in Autistic Disorder. Retrieved August, 2009 from http://www.neuropharm.co.uk/media_centre/news_release/?page=2&id=3542

  • Oswald, D. P., & Sonenklar, N. A. (2007). Medication use among children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 17(3), 348–355.

    Article  PubMed  Google Scholar 

  • Posey, D., Aman, M., McCracken, J., Scahill, L., Tierney, E., et al. (2007). Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biological Psychiatry, 61(4), 538–544.

    Article  PubMed  Google Scholar 

  • RUPP. (2002). Risperidone in children with autism and serious behavioral problems. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. New England Journal of Medicine, 347(5), 314–321.

    Article  Google Scholar 

  • RUPP. (2005a). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Archives of General Psychiatry, 62(11), 1266–1274.

    Article  Google Scholar 

  • RUPP. (2005b). Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. American Journal of Psychiatry, 162, 1361–1369.

    Article  Google Scholar 

  • RUPP. (2007). A pilot study of parent management training in children with pervasive developmental disorder. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Behavioral Interventions, 22, 179–199.

    Article  Google Scholar 

  • Scahill, L., & Martin, A. (2005). Psychopharmacology. In F. R. Volkmar, R. Paul, A. Klin, & D. J. Cohen (Eds.), Handbook of Autism and Pervasive Developmental Disorders (3rd ed., pp. 1102–1117). Hoboken, NJ: Wiley.

    Google Scholar 

  • Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589–598.

    Article  PubMed  Google Scholar 

  • Scahill, L., Aman, M., McDougle, C., Arnold, L., McCracken, J., & Handen, B. (2009). Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 39(5), 720–729.

    Article  PubMed  Google Scholar 

  • Scahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., et al. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry, 158(7), 1067–1074.

    Article  PubMed  Google Scholar 

  • Scahill, L., McDougle, C. J., Williams, S. K., Dimitropoulos, A., Aman, M. G., et al. (2006). Children’s Yale-Brown obsessive compulsive scale modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45(9), 1114–1123.

    Article  PubMed  Google Scholar 

  • Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., et al. (1997). Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 844–852.

    Article  PubMed  Google Scholar 

  • Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634–e641.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale Child Study Center, Yale School of Medicine, New Haven, CT, USA

    Lawrence Scahill & Susan Griebell Boorin

Authors
  1. Lawrence Scahill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Griebell Boorin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Yale Child Study Center, South Frontage Rd. 230, New Haven, 06520, Connecticut, USA

    Brian Reichow

  2. Center for Autism Research, The Children's Hospital of Philadelphia, Market Street 3535, Philadelphia, 19146, Pennsylvania, USA

    Peter Doehring

  3. Yale Child Study Center, South Frontage Rd. 230, New Haven, 06520, Connecticut, USA

    Domenic V. Cicchetti

  4. Yale Child Study Center, South Frontage Rd. 230, New Haven, 06520, Connecticut, USA

    Fred R. Volkmar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Scahill, L., Boorin, S.G. (2011). Psychopharmacology in Children with PDD: Review of Current Evidence. In: Reichow, B., Doehring, P., Cicchetti, D., Volkmar, F. (eds) Evidence-Based Practices and Treatments for Children with Autism. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-6975-0_8

Download citation

Publish with us

Policies and ethics

Search

Navigation